Many mentions, like the posts referring to 'state-of-the-art review' or 'advances in risk stratification,' reveal an interest in recent improvements in prostate cancer management. The tone is generally informative and appreciative, especially in posts describing the article as 'excellent' or 'comprehensive,' which points to high impact on both public understanding and medical awareness.
AgreementModerate agreement
Most mentions accurately reflect the article's statistics and emphasis on prostate cancer as the most common non-skin cancer in men, showing overall positive recognition of its importance.
InterestHigh interest
Mentions consistently highlight advances, statistics, and management strategies, indicating high curiosity about recent developments and comprehensive understanding.
EngagementModerate engagement
Several mentions explore implications for treatment and diagnosis, such as discussing risk factors, survival rates, and new therapies, suggesting deep engagement.
ImpactHigh impact
The collective mentions emphasize the significance of early detection, risk factors, and advances in management, underscoring the article's high relevance for public awareness and clinical practice.
Abstract in brief
Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299,010 new cases and 35,250 deaths in 2024, and it is the second most common cancer worldwide with 1,466,680 new cases and 396,792 deaths in 2022.
Over 99% of prostate cancers are adenocarcinoma, with the median age at diagnosis being 67 years, and more than 50% of risk factors are genetic, while older age and Black race significantly increase risk; for example, the incidence rate is 173.0 cases per 100,000 Black men compared to 97.1 per 100,000 White men.
Most patients (about 75%) are diagnosed with localized cancer, which has nearly a 100% 5-year survival rate, and management options include active surveillance, prostatectomy, or radiation therapy based on risk, while approximately 10% present with metastatic disease, which has a 5-year survival rate of 37%, treated mainly with androgen deprivation therapy and newer androgen receptor pathway inhibitors like abiraterone.
For those curious to learn more about prostate cancer following Joe Biden’s diagnosis, here is a state-of-the-art review ?
https://t.co/ZbhICvBdRA https://t.co/UT5OzA8UD6
May 18, 2025 · 608 likes · 127 shares · 215,171 followersView post →
MA
Mauricio Ambriz
@AmbrizMau · X
Mecanismos de los fármacos utilizados en la terapia sistémica del cáncer de próstata:
JAMA 2025; DOI: 10.1001/jama.2025.0228 https://t.co/O15yRfcieM
Mar 21, 2025 · 214 likes · 41 shares · 72,605 followersView post →
YE
Yakup Ergün
@dr_yakupergun · X
A great review on prostate cancer
Treatment algorithm?
https://t.co/74RDvwsrPH https://t.co/r8Ha8U7Lix
Mar 11, 2025 · 187 likes · 77 shares · 7,722 followersView post →
KS
Keith Siau
@drkeithsiau · X
Therapies for prostate cancer ??
?: https://t.co/LFzgZdcZme https://t.co/l1cvbhwMJL
? Prostate cancer remains the most common non-skin cancer in men, with >1.4M cases annually worldwide.
Advances in risk stratification, AR pathway inhibitors & chemo are reshaping management, but metastatic disease survival is still poor.
? @JAMA_current
DOI ?? 10.1001/jama.2025.0228
#CánCare #oncology #prostatecancer
Aug 25, 2025 · 86 likes · 30 shares · 2,534 followersView post →
EC
Elena Castro
@Ecastromarcos · X
Excellent review on prostate cancer https://t.co/rlQ5pnBJEQ https://t.co/fayLUVjhEy
Prostate cancer is the most common nonskin cancer in men in the US and the second most common cancer worldwide. This video features expert insights on the epidemiology, diagnosis, and treatment strategies for localized…
Early detection of cancer dramatically increases survival chances, with success rates over 99% for localized prostate cancer. Symptoms often appear only in advanced stages, making timely diagnosis crucial for effective…
? Prostate cancer remains the most common non-skin cancer in men, with >1.4M cases annually worldwide.
Advances in risk stratification, AR pathway inhibitors & chemo are reshaping management, but metastatic disease survival is still poor.
? @JAMA_current
DOI ?? 10.1001/jama.2025.0228
#CánCare #oncology #prostatecancer
Aug 25, 2025 · 86 likes · 30 shares · 2,534 followersView post →
Did you know? At diagnosis, approximately 75% of patients have cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%.
https://t.co/ocnsxzTaX5
For those curious to learn more about prostate cancer following Joe Biden’s diagnosis, here is a state-of-the-art review ?
https://t.co/ZbhICvBdRA https://t.co/UT5OzA8UD6
May 18, 2025 · 608 likes · 127 shares · 215,171 followersView post →
AM
Alper Topal, MD
@dralpertopal · X
An excellent Prostate Cancer review from JAMA??
https://t.co/BC1mgkXzAF https://t.co/bZmsChxwiK
Apr 22, 2025 · 1 like · 1,216 followersView post →
T
Truthoverdishonesty
@Nigelj08223326 · X
Prostate Cancer https://t.co/R1WXiLZYZ8
Management includes
active surveillance
prostatectomy
radiation therapy, depending on risk of progression
10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%
@joeurol @SirGeoffPalmer
Mar 28, 2025 · 1 like · 1 share · 1,683 followersView post →
DG
Diego A. Díaz-García
@diegoadiazg · X
Prostate Cancer: A Global Perspective
? Localized (75%) → ~100% 5-year survival, treated with surveillance, surgery, or radiation.
? Metastatic (10%) → 37% 5-year survival, managed with ADT, androgen receptor inhibitors & chemo.
Advances in precision medicine and targeted therapies continue to shape the tx landscape, offering hope for improved outcomes.
? @JAMA_current
? DOI: 10.1001/jama.2025.0228
Mar 24, 2025 · 5 likes · 2 shares · 2,534 followersView post →
BV
Bruno Vellas
@brunovellas · X
Prostate Cancer https://t.co/UTg2TIiASC
Mar 24, 2025 · 1 like · 2,553 followersView post →
MA
Mauricio Ambriz
@AmbrizMau · X
Mecanismos de los fármacos utilizados en la terapia sistémica del cáncer de próstata:
JAMA 2025; DOI: 10.1001/jama.2025.0228 https://t.co/O15yRfcieM
Mar 21, 2025 · 214 likes · 41 shares · 72,605 followersView post →
Mar 18, 2025 · 9 likes · 6 shares · 21,713 followersView post →
FH
Fred Hutch
@fredhutch.org · Bluesky
Fred Hutch/@uwmedicine.bsky.social's Dan Lin, Bruce Montgomery and Ruben Raychaudhuri recently published an overview of #prostatecancer (PC) in @jama.com. PC is the most common non-skin cancer in men in the U.S. with ~300K new cases and 35K deaths in 2024. pubmed.ncbi.nlm.nih.gov/40063046/ 1/12
Fred Hutch/@UWMedicine's @DanLinMD, Bruce Montgomery and Ruben Raychaudhuri published an overview of #prostatecancer in @JAMA_current. Prostate cancer is the most common non-skin cancer in men in the U.S. with ~300K new cases and 35K deaths in 2024. 1/12 https://t.co/dHwVxV5F0K
Mar 17, 2025 · 3 likes · 38,322 followersView post →
P
pinacol
@pinacol · X
【総説】前立腺癌 #ペ読
https://t.co/tSmpgsctct
Mar 16, 2025 · 1 like · 1,759 followersView post →
A great new general review on prostate cancer that is just out. Nicely covered by a leading edge and balanced group of physician-investigators for a very complex topic! ? @jama.com jamanetwork.com/journals/jam...
Excellent concise review on prostate cancer https://t.co/E1IZCiFMwq
Mar 11, 2025 · 1 like · 1,114 followersView post →
AR
Ana Rosa Rubio
@AnaRRubio · X
Prostate Cancer: A Review
https://t.co/mJCMmBkxzd
Mar 11, 2025 · 2 likes · 1,358 followersView post →
YE
Yakup Ergün
@dr_yakupergun · X
A great review on prostate cancer
Treatment algorithm?
https://t.co/74RDvwsrPH https://t.co/r8Ha8U7Lix
Mar 11, 2025 · 187 likes · 77 shares · 7,722 followersView post →
GO
Global Health Observ
@GlobalPHObserv · X
Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024.
https://t.co/0nWBFjYmTL
Mar 11, 2025 · 4 likes · 3 shares · 6,690 followersView post →
LR
Lucia Ruggiero
@lruggiero.bsky.social · Bluesky
Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024.
jamanetwork.com/journals/jam...
To refresh information about prostate cancer, a good review from @JAMANetwork
#oncology #prostatcancer
https://t.co/Wm57jVWYTu https://t.co/HYhLjVqsQj
Mar 11, 2025 · 15 likes · 2 shares · 1,416 followersView post →
AP
Ash Paul
@pash22 · X
Prostate Cancer: A Review
https://t.co/RrW4RbFVCT via @RubenRaychaud et al
Mar 11, 2025 · 4 likes · 2 shares · 33,646 followersView post →
DD
Dr. Gennadi Glinsky, MD, Ph.D.
@gglinskii · X
Prostate Cancer: A Review
https://t.co/tj2cGeIZjP
Mar 11, 2025 · 2 likes · 1,975 followersView post →
PA
Prof. Dr. Josep Vidal-Alaball
@jvalaball · X
Prostate Cancer https://t.co/P7pxSSNXqf
Mar 10, 2025 · 1 like · 14,620 followersView post →
N
Diabetes Worsens In-Hospital Outcomes in Hospitalized Prostate ...
News
JAMA. 2025;333(16):1433–1446. https://doi.org/10.1001/jama.2025.0228. 8. Adzavon YM, Culig Z, Sun Z. Interactions between androgen and IGF1 axes in prostate ...
Brasil - Notificações de câncer relacionado ao trabalho no ... - SciELO
News
JAMA. 2025 Apr;333(16):1433-46. https://doi.org/10.1001/jama.2025.0228 » https://doi.org/10.1001/jama.2025.0228; 13 Instituto Brasileiro de Geografia e ...
Cervical Lymphadenopathy as Initial Presentation of Foamy Gland ...
News
JAMA Otolaryngol Head Neck Surg. 2024;150(2):172–178. doi:10.1001/jamaoto ... doi:10.1001/jama.2025.0228. (Open in a new window)PubMed (Open in a new ...
'Conquering the Challenging Cases in mCSPC/mCRPC' - CRSF
News
JAMA. 2025;333(16):1433-1446. doi:10.1001/jama.2025.0228. • Median age at diagnosis ~67 years. • More than 50% of prostate cancer risk is attributable to ...
JAMA. 2025;333(16):1433-1446. doi: 10.1001/jama.2025.0228. 2. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. Shipley WU ...